Drugs / DB-1305
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06953089 | Jul 2025 → Jun 2030 expected | cancer | DualityBio Inc. | Recruiting | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2024-01-31 | BioNTech SE | BioNTech and DualityBio Receive FDA Fast Track Designation for Next-Generation Antibody-Drug Conjugate Candidate BNT325/DB-1305 biontech.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DB-1305 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06953089 ↗ |
| Known as | BNT325 | “DB-1305/BNT325” NCT06953089 ↗ |
| Route | Intravenous | “Administered I.V.” NCT06953089 ↗ |